SEC Company Response from RAPT Therapeutics, Inc. (RAPT) (CIK 0001673772) (RAPT) — Jun 27, 2022
RAPT Therapeutics, Inc. (RAPT) (CIK 0001673772)
Date: June 27, 2022 · CIK: 0001673772 · Accession: 0001193125-22-182709
AI Filing Summary & Sentiment
File numbers found in text: 333-265812
Show Raw Text
CORRESP 1 filename1.htm CORRESP RAPT Therapeutics, Inc. 561 Eccles Avenue South San Francisco, California, 94080 June 27, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: RAPT Therapeutics, Inc. Registration Statement on Form S-3 Filed June 24, 2022 File No. 333-265812 To whom it may concern: Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, RAPT Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-265812) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on June 29, 2022 or as soon as practicable thereafter. The Company requests that we be notified of such effectiveness by a telephone call to Courtney M.W. Tygesson of Cooley LLP at (312) 881-6500 and that such effectiveness also be confirmed in writing. Very truly yours, RAPT Therapeutics, Inc. By: /s/ Rodney Young Rodney Young Chief Financial Officer cc: Courtney M.W. Tygesson, Cooley LLP